Tempus is a company that is working diligently on changing the outcomes of people diagnosed with cancer. Specifically, this forward thinking company founded by Eric Lefkofsky is using genomic data to help physicians identify the the best treatment options on a personalized basis. The bottom line is simple: not all cancers act the same. The disease mutates and changes based on a number of factors in the human body. Studying these changes at a molecular level can help doctors pinpoint better treatment options, therefore can help to prevent and cure this insidious disease. That is the goal of Tempus.
By partnering with major hospital systems such as the Mayo Clinic as well as the University of Michigan and Northwestern’s Lurie Cancer Center, Tempus is actively working with doctors and other health professionals to personalize each patient’s treatment plan. Cancer is certainly not a “one size fits all” disease, and it stands to reason that what works for one patient doesn’t necessarily work for another. There are so many factors that are part of the disease process and it is important to find out how each factor affects the disease process as well as the treatment process.
As co-founder and CEO of Tempus, Lefkofsky and his team are working aggressively to give doctors and other healthcare professionals the tools to become more effective. This means that doctors will be able to ascertain very quickly whether a particular treatment plan is actually the best option or not. And due to the fact that some cancers move very quickly and also escape detection for long periods of time, this technology and research could mean the difference between life and death. Medical science and cancer treatments continue to evolve and Tempus is at the forefront of the much needed technology that patients today need.
If you’re not too familiar with cancer research then you’re probably unaware of some very talented individuals. The fight against cancer is at an all-time high and there have been many advanced breakthroughs over the past 16 years. Many of the medications currently used today are much more effective than medications of the past. SeattleGenetics is one of the leaders when it comes to advanced breakthrough therapies. The organization has well 800 employees, been ranked by Forbes as one of the fastest growing companies in the nation, and it produces some of the very best cancer fighting drugs. With any great company/business, there has to be great leadership and Seattle Genetics is no exception.
Clay Siegall is the man of the hour and he’s doing everything in his power to eradicate the world of this deadly disease. He’s a man of many talents because of his broad educational background. He’s known by many as a philanthropist, doctor, scientist, guest speaker, and author. Dr. Siegall has been in the game for many years and has worked with many of the biggest names in cancer research such as The National Institute of Health, The National Cancer Institute, and Bristol Myers Squibb. Dr. Siegall studied at George Washington University and received a Ph.D in Genetics. He also studied at The University of Maryland where he received a (BS) in Zoology. As you can see, the guy is clearly in a class of his own. Being the President, CEO, and a Founder of Seattle Genetics, Dr. Siegall has built a strong structure to work from. He implements his three main functions to success being rigorous research, drug development, and scientific innovation. This way of thinking has pushed the organization ahead of it’s competitors and it’s flagship drug (ADCETRIS), has racked up hundreds of million in Canada and the U.S.
This year, the Puget Sound research community was visited by the Vice President, Joe Biden. The visit has made the community very popular. One of the growing communities in the area that the vice president visited was Seattle Genetics, a company that has transformed the lives of many cancer patients in the recent past.
Seattle Genetics is one of the growing Biotechnology pharmaceutical companies in the world, and it is putting a lot of effort to ensure that its first drug which was introduced several years ago is used by the growing number of cancer patients in the world. The company is planning to hire more professionals to enable it expand its services to the consumers.
Cancer is one of the most feared diseases in the world. However, the number of people suffering from the diseases continues to grow every day. Seattle Genetics wants to increases its products so that it can help these individuals. Currently, Seattle Genetics, under the leadership of its founder and CEO is working hard to commercialize its first drug, known as Adcetris. Adcetris is being tested on several types of lymphomas.
Adcetris, the only product from Seattle Genetics is mostly used by patients who are fighting lymphomas. The product is doing quite well in the places it has been taken, and in Canada and the United States, it registered very high sales last year. Takeda Pharmaceuticals, one of the partners of Seattle Genetics is currently trying to introduce the product in other parts of the world.
Apart from Adcetris, Seattle Genetics has not been able to introduce any other cancer
drug in the market. However, reports from the pharmaceutical company say that more drugs are being developed. Twelve drugs are currently being developed by Seattle Genetics CEO, and they will all be made for individuals suffering from different types of cancer.
33A, the second product from the institution will soon be introduced to the market this year. It will be used to treat individuals with acute myeloid leukemia. Seattle Genetics will also be introduced a drug for bladder cancer and breast cancer.
Clay B Siegal is the Chief Executive Officer (CEO), the President and the Chairman of the Board of the Seattle Genetics company. Seattle Genetics was founded in 1998, and Clay Siegall was among the founders. He was a trained scientist, and his company was created based on scientific innovations and the desire to assist patients. Clay has been a great leader, and he has been able to manage the organization all through and currently it develops an antibody-drug conjugate (ADCs) that treats cancer.
Clay Siegall has been able to push Seattle Genetics into some strategic licenses particularly for technology such as Roche, Pfizer, AbbVie, and GlaxoSmithKline. He decided to separate the money-raising activities which secure millions of dollars via public and private financing, for example, the Initial Public Offer (IPO) that was conducted in 2001. In January 2014, Dr. Siegall who is also a Ph.D. holder joined Ultragenyx as the member of the board. Before he co-founded Seattle Genetics, Dr. Siegall was working for the Bristol-Myers Squibb Pharmaceutical Research Institute between1991 and 1997. He also worked for the National Cancer Institute and National Institute of Health between 1988 and 1991. Mr. Clay Siegall is a member of the board of directors of two private biotechnology companies; Mirna Therapeutics and BioPharmaceuticals. Siegall is a B.S in Zoology graduate from the University of Maryland. Later on, Siegall joined George Washington University for Ph.D. in Genetics.
Mirna Therapeutics appointed Clay Siegall as an outside board of directors on January 30, 2013. Mirna was in need of his long-term experiences in the pharmaceutical industry, which will help Mirna in their journey to modify the development of microRNA-based therapeutics. Dr. Siegall views MicroRNA-based therapeutics as an important field of conducting cancer research. He also said that Mirna contains employees who are productive. Siegall also stated that he is very pleased to be appointed as an outside board of directors and he is ready to cooperate with other members to modify its important systems for patients. Besides the mentioned achievements, Dr. Siegall is also an author who holds 15 patents, and he has completed many publications.
The current trend in cancer treatment is to enable the immune system of the patient to eradicate the tumors instead of using chemotherapy to target the cancer cells. Seattle Genetics is a leading biotechnology firm that specializes in development and commercialization of advanced antibody-based therapies for cancer treatment. Seattle Genetics is a market leader and supplier of the antibody-drug conjugate, an innovative technology developed to strengthen the targeting capability of monoclonal antibodies in delivering cell-killing agents straight to the cancer cells. ADCs are designed to avoid non-targeted cells hence minimizing harmful effects associated with traditional chemotherapy and promoting antitumor activity.
ADCETRIS is Seattle’s top program and an innovative class of ADCs. The drug has been approved in over 60 countries. The firm is currently carrying out a clinical development program to evaluate if ADCETRIS can treat CD30-expressing lymphomas such as cutaneous T-cell lymphoma, mature T-cell lymphomas, and Hodgkin lymphoma.
This ADC is being examined in pivotal phase 3 experimentation for the treatment of acute myeloid leukemia (AML). AML is a vital unmet need since patient outcomes have remained unchanged for over 30 years.
33A and ADCETRIS are part of over 20 ADCs currently in clinical development utilizing Seattle Genetics’ proprietary technology such as over 12 internal clinical as well as preclinical programs. The company is striving to come up with a lasting solution for solid tumors and hematologic malignancies.
Clay B. Siegall was one of the co-founders of Seattle Genetics in 1998, and he currently serves as the CEO, Board Chairman, and President. He is a trained scientist who has specialized in targeted cancer therapies. He created Seattle Genetics on a firm basis of scientific innovation, thorough research, drug creation practices, and commitment to helping patients. He has played an integral role in steering the company to a top position in the health care industry and in obtaining the authorization of its first innovative ADC product by the FDA. Dr. Siegall has led Seattle Genetics in entering into several tactical licenses for its groundbreaking ADC technology with AbbVie, Pfizer, Genentech, and GlaxoSmithKline, which have produced over $325 million.